{"success":true,"data":{"pressRelease":{"id":"16938","rtpr_id":"nACSnzDHha","ticker":"TNON","exchange":"NASDAQ","all_tickers":["TNON"],"title":"Tenon Medical, Inc. Sets Date for First Quarter 2026 Earnings","author":"ACCESSWIRE","published_at":"2026-05-01T12:00:00.777Z","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Tenon Medical, Inc. (https://pr.report/l72n) (NASDAQ:TNON) (\"Tenon\" or\nthe \"Company\"), a company redefining care for patients suffering from\nsacro-pelvic disorders, today announced plans to release financial results for\nthe first quarter ended March 31, 2026 after market close on Tuesday, May 12,\n2026. The Company will also hold a conference call on the same day at 4:30\np.m. Eastern Time to discuss its financial results in further detail. The call\nwill conclude with a Q&A session with its covering analysts.\n\n Date:                   Tuesday, May 12, 2026                          \n Time:                   4:30 p.m. Eastern time                         \n Dial-in:                1-877-407-0792                                 \n International Dial-in:  1-201-689-8263                                 \n Webcast:                TNON Conference Call (https://pr.report/l72o)  \n\nPlease dial in at least 10 minutes before the start of the call to ensure\ntimely participation.\n\nAn audio playback of the call will be available through May 26, 2026, on\nTenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone\nreplay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The\naccess code will be 13759830.\n\nAbout Tenon Medical, Inc.\n(https://app.accessnewswire.com/imagelibrary/2be6a687-b029-4309-9222-8f4eb9c0f12f/image.jpeg)\nTenon Medical, Inc. is a medical device company founded in 2012 and committed\nto developing novel technologies for patients suffering from debilitating SI\njoint pain and dysfunction. The Company markets the Catamaran(®) and\nSImmetry+(®) SI Joint Fusion Systems, which offer a novel, less invasive\napproach to treating SI joint disease. Together, these platforms uniquely\nposition Tenon with multiple surgical approaches, lateral and\ninferior-posterior, both designed to be minimally invasive, enable authentic\narthrodesis, and supported by robust clinical evidence, including the\npublished prospective Mainsail(™) and EVoluSIon(™) SI joint fusion\nstudies. These differentiated technologies enable physicians to customize\ntreatment plans through an innovative portfolio spanning SI joint fusion,\nspinal fusion, and deformity adjuncts, each solution engineered to deliver\nfusion outcomes more reliably. This multi-platform, multiapproach strategy\nstrengthens Tenon's competitive advantage in the expanding SI joint fusion\nmarket and underscores the Company's commitment to delivering proven, durable\noutcomes for physicians and patients. Tenon is focused on three commercial\nopportunities in the SI joint market: 1) primary SI joint procedures, 2)\nrevision of failed SI joint implants, and 3) augmenting spinal fusion. For\nmore information, please visit www.tenonmed.com.\n\nThe Tenon Medical logo shown above, and Catamaran(®), PiSIF(®), CAT\nPiSIF(®), ETAD(®), Posterior Inferior Sacroiliac Fusion(®), CAT SIJ Fusion\nSystem(®), Catamaran SIJ Fusion System(®), Catamaran Inferior Posterior\nFusion System(®), Catamaran Transfixation Fusion System(®), Catamaran\nTransfixation Fusion Device(®), SImmetry(®) are registered trademarks of\nTenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon\nMedical, Inc.\n\nInvestor Contact\n\nShannon Devine\nMZ North America\n203-741-8811\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medical-inc.-sets-date-for-first-quarter-2026-earnings-1162987)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSnzDHha","title":"Tenon Medical, Inc. Sets Date for First Quarter 2026 Earnings","author":"ACCESSWIRE","ticker":"TNON","created":"2026-05-01T12:00:00.777Z","tickers":["TNON"],"exchange":"NASDAQ","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Tenon Medical, Inc. (https://pr.report/l72n) (NASDAQ:TNON) (\"Tenon\" or\nthe \"Company\"), a company redefining care for patients suffering from\nsacro-pelvic disorders, today announced plans to release financial results for\nthe first quarter ended March 31, 2026 after market close on Tuesday, May 12,\n2026. The Company will also hold a conference call on the same day at 4:30\np.m. Eastern Time to discuss its financial results in further detail. The call\nwill conclude with a Q&A session with its covering analysts.\n\n Date:                   Tuesday, May 12, 2026                          \n Time:                   4:30 p.m. Eastern time                         \n Dial-in:                1-877-407-0792                                 \n International Dial-in:  1-201-689-8263                                 \n Webcast:                TNON Conference Call (https://pr.report/l72o)  \n\nPlease dial in at least 10 minutes before the start of the call to ensure\ntimely participation.\n\nAn audio playback of the call will be available through May 26, 2026, on\nTenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone\nreplay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The\naccess code will be 13759830.\n\nAbout Tenon Medical, Inc.\n(https://app.accessnewswire.com/imagelibrary/2be6a687-b029-4309-9222-8f4eb9c0f12f/image.jpeg)\nTenon Medical, Inc. is a medical device company founded in 2012 and committed\nto developing novel technologies for patients suffering from debilitating SI\njoint pain and dysfunction. The Company markets the Catamaran(®) and\nSImmetry+(®) SI Joint Fusion Systems, which offer a novel, less invasive\napproach to treating SI joint disease. Together, these platforms uniquely\nposition Tenon with multiple surgical approaches, lateral and\ninferior-posterior, both designed to be minimally invasive, enable authentic\narthrodesis, and supported by robust clinical evidence, including the\npublished prospective Mainsail(™) and EVoluSIon(™) SI joint fusion\nstudies. These differentiated technologies enable physicians to customize\ntreatment plans through an innovative portfolio spanning SI joint fusion,\nspinal fusion, and deformity adjuncts, each solution engineered to deliver\nfusion outcomes more reliably. This multi-platform, multiapproach strategy\nstrengthens Tenon's competitive advantage in the expanding SI joint fusion\nmarket and underscores the Company's commitment to delivering proven, durable\noutcomes for physicians and patients. Tenon is focused on three commercial\nopportunities in the SI joint market: 1) primary SI joint procedures, 2)\nrevision of failed SI joint implants, and 3) augmenting spinal fusion. For\nmore information, please visit www.tenonmed.com.\n\nThe Tenon Medical logo shown above, and Catamaran(®), PiSIF(®), CAT\nPiSIF(®), ETAD(®), Posterior Inferior Sacroiliac Fusion(®), CAT SIJ Fusion\nSystem(®), Catamaran SIJ Fusion System(®), Catamaran Inferior Posterior\nFusion System(®), Catamaran Transfixation Fusion System(®), Catamaran\nTransfixation Fusion Device(®), SImmetry(®) are registered trademarks of\nTenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon\nMedical, Inc.\n\nInvestor Contact\n\nShannon Devine\nMZ North America\n203-741-8811\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medical-inc.-sets-date-for-first-quarter-2026-earnings-1162987)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T12:00:00.836160199Z","server_sent_at_ms":1777636800836},"received_at":"2026-05-01T12:00:00.888Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medical-inc.-sets-date-for-first-quarter-2026-earnings-1162987"},"analysis":null,"durationMs":null,"modelName":null}}